• Offers substantial improvements in nucleic acid extraction for molecular diagnostics.
•  Manufactured using cost-effective raw materials, allowing for reasonable pricing.
• User-friendly and requires minimal training, facilitating rapid adoption across institutions.

Customer Competitive Edge

• Improves diagnostic accuracy and operational efficiency.
• Ease of use reduces training time and costs.
• Enables institutions to effectively expand their diagnostic capabilities.
• Provides a robust tool for precise molecular diagnostics without extensive specialized knowledge or infrastructure.

Distinction from Existing Technologies

• Patented innovation not present in competing products.
• Cost-effectiveness due to the use of affordable raw materials.
• Eliminates hazardous substances, enhancing safety and reducing costs.
• Adherence to international quality standards ensures high product reliability.

Performance and Safety Advantages

• Significant improvement in performance over existing nucleic acid extraction methods.
• Safer for laboratory personnel due to the absence of toxic chemicals.
• Reduces environmental impact by eliminating hazardous waste associated with toxic solvents.

Facilitates Rapid Dissemination

• Minimal training requirements accelerate technology adoption.
• Suitable for a wide range of users, expanding the reach of advanced molecular diagnostics.
• Supports better disease monitoring and response efforts by improving pathogen detection in various samples.

The technology is focused on extracting nucleic acids from samples where pathogens are present, but nucleic acid extraction is particularly challenging. The core technology works by adsorbing PCR inhibitors and separating them from the lysate. By purifying only the RNA or DNA that contains crucial information like pathogens, the kit isolates substances that interfere with PCR diagnosis. This process significantly improves the accuracy and sensitivity of molecular diagnostics.

A key innovation is the elimination of toxic organic compounds such as chloroform and phenol, which traditionally necessitate the use of exhaust facilities like fume hoods. By not using these substances, the kit allows a wide range of users to achieve high-quality molecular diagnostic results with minimal training. This makes advanced diagnostic techniques more accessible and safer for various institutions and personnel.

The excellence of the nucleic acid extraction kit lies in its ability to provide reliable results without the need for specialized infrastructure or extensive user training. It addresses the limitations of conventional methods by simplifying the extraction process and reducing the risks associated with hazardous chemicals. This not only enhances laboratory safety but also reduces costs and increases efficiency in disease diagnostics.

By supplying the innovative technology to key national institutions involved in disease control and prevention, the company aim to contribute significantly to public health. The technology facilitates more accurate detection of pathogens in a variety of challenging samples, supporting better disease monitoring and response efforts. 

The company seeks partners who are well-acquainted with government institutions and actively involved in pathogen diagnosis and surveillance. Ideal partners would have a deep understanding of researchers studying disease vectors such as mosquitoes, ticks, sewage, and other carriers of diseases, especially in subtropical regions. They may be universities, national institutions, or research organizations that receive support from European or global agencies. 

The company is seeking collaborations to implement nucleic acid extraction technology, enhancing its research and diagnostic capabilities in the monitoring and study of pathogens. Its role would involve utilizing the technology in its ongoing projects and potentially contributing to its development and dissemination across its networks.